Drug Profile
Genz 682452
Alternative Names: Genz-682452; GENZ68245Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fabry's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Fabry's-disease(In volunteers) in USA (PO, Capsule)
- 28 Feb 2013 Genzyme completes a phase I trial in Healthy volunteers in USA (NCT01710826)
- 31 Jan 2013 Genzyme completes a phase I trial in Healthy volunteers in USA (NCT01674036)